These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 511441)

  • 1. Steroid problems.
    Britto JF
    Int J Dermatol; 1979 Nov; 18(9):765. PubMed ID: 511441
    [No Abstract]   [Full Text] [Related]  

  • 2. Contact dermatitis to desonide.
    Sturtz RP; Rau RC
    Arch Dermatol; 1983 Dec; 119(12):1023. PubMed ID: 6228195
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical comparison of desonide cream with fluocinonide cream in steroid-responsive dermatologic disorders.
    Barsky S
    Cutis; 1976 Dec; 18(6):826-30. PubMed ID: 797554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Control of the bioavailability of a topical steroid; comparison of desonide creams 0.05% and 0.1% by vasoconstrictor studies and clinical trials.
    Barry BW; Fyrand O; Woodford R; Ulshagen K; Hogstad G
    Clin Exp Dermatol; 1987 Nov; 12(6):406-9. PubMed ID: 3333023
    [No Abstract]   [Full Text] [Related]  

  • 5. [Steroid-induced atrophy of cutis propria].
    Groniowska M; Walski M; Groniowski J
    Reumatologia; 1978; 16(1):113-6. PubMed ID: 674900
    [No Abstract]   [Full Text] [Related]  

  • 6. Potency ranking of two new topical corticosteroid creams containing 0.1% desonide or 0.05% halometasone utilising the human skin blanching assay.
    Meyer E; Smith EW; Haigh JM; Kanfer I
    Arzneimittelforschung; 1988 Dec; 38(12):1840-3. PubMed ID: 3245859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and analysis of a degradation product of the glucocorticoid desonide in ointment.
    Nguyen TT; Kringstad R; Aasen AJ; Rasmussen KE
    Acta Chem Scand B; 1988 Jul; 42(6):403-7. PubMed ID: 3195294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview on desonide 0.05%: a clinical safety profile.
    Wong VK; Fuchs B; Lebwohl M
    J Drugs Dermatol; 2004; 3(4):393-7. PubMed ID: 15303783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of extraction columns for the isolation of desonide and parabens from creams and ointments for high-performance liquid chromatographic analysis.
    Nguyen TT; Kringstad R; Rasmussen KE
    J Chromatogr; 1986 Sep; 366():445-50. PubMed ID: 3782330
    [No Abstract]   [Full Text] [Related]  

  • 10. Perilymphatic subcutaneous atrophy in adnexal hemangioma: a complication of intralesional corticosteroid injection.
    Ford MD; Codere F
    Ophthalmic Surg; 1990 Mar; 21(3):215-7. PubMed ID: 2348971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the effect of phenylbutazone, desonide and cyclophosphamide on four types of experimental pleurisy.
    Tarayre JP; Lauressergues H
    J Pharm Pharmacol; 1980 Jun; 32(6):408-12. PubMed ID: 6106673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Non-halogenated glucocorticoids. A clinical comparison between budesonide 0,025% ointment and desonide 0,1% ointment in psoriasis].
    Granholt A; Malmsten LA
    Tidsskr Nor Laegeforen; 1983 May; 103(15):1266-8. PubMed ID: 6349008
    [No Abstract]   [Full Text] [Related]  

  • 13. Desonide: a review of formulations, efficacy and safety.
    Kahanek N; Gelbard C; Hebert A
    Expert Opin Investig Drugs; 2008 Jul; 17(7):1097-104. PubMed ID: 18549345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GLC analysis of hydrocortisone, triamcinolone acetonide, and desonide in culture media of mouse and human dermal fibroblasts using flame-ionization detection.
    Au DS; Runikis JO; Abbott FS; Burton RW
    J Pharm Sci; 1981 Aug; 70(8):917-23. PubMed ID: 7310664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Skin and fat atrophy complications of local steroid injection.
    Di Stefano V; Nixon JE
    Pa Med; 1974 Jan; 77(1):38. PubMed ID: 4809750
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of the cutaneous/systemic antiinflammatory activity ratios for desonide and hydrocortisone in various experimental models.
    Tarayre JP; Aliaga M; Barbara M; Ballester R; Tisné-Versailles J; Couzinier JP
    Arzneimittelforschung; 1988 Apr; 38(4):542-5. PubMed ID: 3401268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corticosteroid-induced atrophy of the skin with telangiectasia. A clinical and experimental study.
    Stevanović DV
    Br J Dermatol; 1972 Dec; 87(6):548-56. PubMed ID: 4648801
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical comparison of alclometasone dipropionate and desonide ointments (0.05%) in the management of psoriasis.
    Frost P; Horwitz SN
    J Int Med Res; 1982; 10(5):375-8. PubMed ID: 6754511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atrophy of the skin. The clinical problems.
    Sneddon IB
    Br J Dermatol; 1976 Mar; 94 suppl 12():121-3. PubMed ID: 1268072
    [No Abstract]   [Full Text] [Related]  

  • 20. Desonide foam: a review.
    Parish D; Scheinfeld N
    Drugs Today (Barc); 2008 Jan; 44(1):55-62. PubMed ID: 18301804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.